<DOC>
	<DOC>NCT00733863</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with mild Alzheimer's disease.</brief_summary>
	<brief_title>Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis of Mild Alzheimer's Disease MiniMental State Examination (MMSE) 20 to 26 at screening, untreated or on stable dose of cholinesterase inhibitor or memantine over the last 6 weeks Previously participated in an AD vaccine study and received active treatment History or presence of an active autoimmune and/or with an acute or chronic inflammation, and/or clinically relevant atopic condition. History or presence of seizures and/or cerebrovascular disease. Presence of an other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression)</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Active immunization</keyword>
	<keyword>Alzheimer disease</keyword>
	<keyword>Antibody</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Neurodegenerative diseases</keyword>
	<keyword>Vaccine</keyword>
</DOC>